The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Bevacizumab plus capecitabine as a salvage therapy in advanced adrenocortical carcinoma
Abstract
OBJECTIVE: No standard therapy for advanced adrenocortical carcinoma (ACC) is established by any randomized trial but a consensus conference 2003 recommended mitotane as monotherapy or combined with etoposide, doxorubicin and cisplatin or with streptozotocin as first-line systemic therapy. However, there is no evidence for any therapy beneficial in patients failing these therapies. Therefore, we evaluated the effects of the anti-VEGF antibody bevacizumab plus capecitabine as salvage therapy in ACC. METHODS: Patients registered with the German ACC Registry with refractory ACC progressing after cytotoxic therapies were offered treatment with bevacizumab (5 mg/kg body weight i.v. every 21 days) and oral capecitabine (950 mg/m(2) twice daily for 14 days followed by 7 days of rest) in 2006-2008. Evaluation of tumour response was performed by imaging according to response evaluation criteria in solid tumours every 12 weeks. RESULTS: Ten patients were treated with bevacizumab plus capecitabine. None of them experienced any objective response or stable disease. Two patients had to stop therapy after few weeks due to hand-foot syndrome, and three patients died on progressive disease within 12 weeks. Other adverse events were mild (grade I-II). Median survival after treatment initiation was 124 days. CONCLUSIONS: Bevacizumab plus capecitabine has no activity in patients with very advanced ACC. Hence, this regimen cannot be recommended as a salvage therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, overexpression of VEGFR type 2 in ACC samples was observed by immunohistochemistry (239).”
From Adrenocortical carcinoma (2014) · cites this paper as [239]
In the citing paper
“However, an earlier clinical trial using bevacizumab, an anti-VEGF monoclonal antibody, proved to be ineffective (239).”
From Adrenocortical carcinoma (2014) · cites this paper as [239]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
Yang, J. C., Haworth, L. R., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,704
Cassidy, J., Clarke, S. J., Díaz‐Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S. L., Lichinitser, M., Yang, T., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 861
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Self-citationAdjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Faßnacht, M., Daffara, F., Tauchmanovà, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E. M., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 759
Self-citationFassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Self-citationIcard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Cited by
Sorted by citations
Items 101–132 of 132
Shekar, S., Hall, A., Pham, J. P., Crumbaker, M., Liu, J., Talmor, B., Sim, H., & Joshua, A. M. (2025) · Endocrine Oncology · doi:10.1530/eo-25-0027 · Cited by 1
Molecular Target Agents in Adrenocortical Carcinoma: Rationale and Difficulties in Trial Design
Ferrari, L., Grisanti, S., Sigala, S., Consoli, F., Terzolo, M., & Berruti, A. (2014) · International Journal of Endocrine Oncology · doi:10.2217/ije.14.11 · Cited by 1
Nikpanah, M., Farhadi, F., Morris, M. A., Nilubol, N., Hoang, C. D., Roper, N., Hernandez, J. M., Chen, C. C., Bergsland, E. K., Wood, B. J., et al. (2022) · Clinical and Translational Imaging · doi:10.1007/s40336-022-00485-w · Cited by 1
Uncommon Adrenal Tumors in Children and Adolescents
Ribeiro, R. C., Galindo, C. R., Pinto, E. M., Zambetti, G. P., & de Figueiredo, B. C. (2012) · Wiley eBooks · doi:10.1002/9781118464557.ch67 · Cited by 1
Diagnosis and Management of Adrenocortical Carcinomas
Orhan, B., Dızdar, Ö., & Yalçın, Ş. (2015) · Springer eBooks · doi:10.1007/978-3-662-45215-8_23
Carcinoma córtico-adrenal. Revisión de la literatura
Rivas, G., Arango, N., Rubiano, J., Vargas, Y., Sánchez, O., Garavito, G., López, J. C., Quintero, J. A., Grosso, F., Durango, I. C., et al. (2012) · Revista Colombiana de Cancerología · doi:10.1016/s0123-9015(12)70023-9
New Perspectives on Diagnostics, Prognosis, and Therapy in Aggressive Endocrine Tumours
Appetecchia, M., Wolffenbuttel, B. H. R., & AlJadir, S. J. (2012) · Journal of Oncology · doi:10.1155/2012/820938
Systemic therapy for advanced adrenal cancer
Dreicer, R. (2012) · Journal of Surgical Oncology · doi:10.1002/jso.23078
Lerário, A. M., Giordano, T. J., & Hammer, G. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-416006-4.00025-9
Local Control of Steroid Hormone Biosynthesis
Hofland, J. (2012) · EUR Research Repository (Erasmus University Rotterdam)
Therapies for Locally Advanced and Metastatic Adrenocortical Carcinoma
Rao, S. N., & Habra, M. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-44136-8_14
Medikamentöse Therapie des Nebennierenkarzinoms
Megerle, F., & Faßnacht, M. (2017) · Der Onkologe · doi:10.1007/s00761-017-0312-9
Adrenal Cortical Carcinoma and Pheochromocytoma
Dreicer, R., Ornstein, M. C., Mittal, K., REYNOLDS, J. P., Klink, J. C., Przybycin, C. G., & Garcia, J. A. (2018) · Wiley eBooks · doi:10.1002/9781118592168.ch37
Phan, A. T., Habra, M. A., Grubbs, E. G., & Moran, C. A. (2012) · Wiley eBooks · doi:10.1002/9781118464557.ch10
Molecular biomarkers and treatment outcomes in advanced genitourinary malignancies
Lavoie, J. (2019) · cIRcle (University of British Columbia) · doi:10.14288/1.0387340
Allolio, B., & Faßnacht, M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00107-4
Self-citationAnálise dos genes ATRX e ZNRF3 como fatores de prognóstico do carcinoma adrenocortical
Balderrama-Brondani, V. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2021.tde-28092021-123423
Stewart, A. A., & Story, E. S. (2017) · Wiley eBooks · doi:10.1002/9781119196235.ch47
AL-Mamari, S. A., & Al-Busaidy, S. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-16301-7_27
Сurrent status of adrenocortical cancer therapy
Фогт, С. Н., Kalugina, V. V., Ворохобина, Н. В., Kuznetsova, A. V., & Павловна, С. И. (2022) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2022-13-2-154-161
Zhulikov, Y. А., Kovalenko, E. I., Bokhyan, V. Y., Khoroshilov, M. V., Goryainov, D. A., Александровна, Р. А., Magamedova, S. S., Евдокимова, Е. В., & Артамонова, Е. В. (2022) · Surgery and Oncology · doi:10.17650/2686-9594-2022-12-3-36-42
Orhan, B., Dızdar, Ö., Yalçın, Ş., & Yıldız, Ö. (2024) · Springer eBooks · doi:10.1007/978-3-031-56968-5_24
Subramanian, C., McNamara, K., Hess, D. L., Croslow, S. W., Tan, Y., Kiseljak‐Vassiliades, K., Wierman, M. E., Sweedler, J. V., & Cohen, M. S. (2025) · Surgery · doi:10.1016/j.surg.2025.109702
Patched as a new target for adrenocortical carcinoma treatment
Hasanovic, A. (2018) · theses.fr (ABES) · doi:10.70675/e4759414z32e1z4e77zbb6fz743df9c365d0
Radiopharmaceutical Theranostics in Primary Adrenal Malignancies: A Surgeon’s Perspective
Laskou, S., Geropoulos, G., Radu, P. A., Pîrvu, C. A., Şurlin, V., Kosmidis, C. S., Psarras, K., Pantea, Ș., Strâmbu, V., & Sapalidis, K. (2026) · Pharmaceuticals · doi:10.3390/ph19050664
ENPP3 CAR T cells combined with CD206 modulation suppress adrenocortical carcinoma
Okada, R., Mendoza, A., Nousome, D., Mathur, S., Rodríguez, C., Maiarana, J., Oh, J., Pendo, K., Phadke, I., Qin, H., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013726
Metadata
- Authors
- Wortmann, S., Quinkler, M., Ritter, C., Kroiss, M., Johanssen, S., Hahner, S., Allolio, B., & Fassnacht, M.
- Affiliations
- University of Würzburg (DE)
- Corresponding author
- Fassnacht, Martin
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-02
- Volume
- 162
- Issue
- 2
- Pages
- 349-356
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2093713748
- Cited by
- 133
- References
- 36
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 3 · 2023: 2 · 2022: 6 · 2021: 13 · 2020: 7 · 2019: 8 · 2018: 10 · 2017: 8 · 2016: 10 · 2015: 12 · 2014: 10 · 2013: 10 · 2012: 15
- FWCI
- 9.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Keywords
- adrenocortical carcinoma, bevacizumab, capecitabine, salvage therapy, anti-VEGF therapy, refractory disease, hand-foot syndrome, treatment efficacy, survival
- MeSH terms
- Bevacizumab, Capecitabine, Adrenal Cortex Neoplasms, Adult, Aged, Antibodies, Monoclonal, Antimetabolites, Antineoplastic, Deoxycytidine, Drug Therapy, Combination, Female, Fluorouracil, Humans, Male, Middle Aged, Severity of Illness Index, Survival Rate, Salvage Therapy, Treatment Failure, Adrenocortical Carcinoma, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
